



1

KHC Office Hours

May 28th, 2025

Kansas Maternal and Child Health

Severe Hypertension in Pregnancy: A Comprehensive Approach for Kansas

Jill Nelson- Kansas Department of Health and Environment
Terrah Stroda, CNM- Kansas Perinatal Quality Collaborative





Kansas Healthcare

COLLABORATIVE



KHA
Kansas Hospital
ASSOCIATION

2

Kansas Healthcare Collaborative
www.khconline.org

1

DISCLAIMER

All Kansas Healthcare Collaborative, Inc. (“KHC”) content and information in KHC’s publications, presentations, and on KHC’s website (“**KHC Content**”) are for informational and educational purposes only. KHC Content does not create any type of relationship with, or duty to, the reader, attendee, or user. KHC Content does not constitute legal, tax, business, professional, or personal advice. KHC disclaims any and all liabilities and warranties, express or implied, arising from users’ access and use of KHC Content.

Today’s Webinar Agenda

- Welcome – 5 mins
- Content Presentation 45 mins
- Q&A 5 Mins
- Closing Comments 2 mins

AGENDA



Severe Hypertension in Pregnancy: A Comprehensive Approach for Kansas

Jill Nelson- Kansas Department of Health and Environment
Terrah Stroda, CNM- Kansas Perinatal Quality Collaborative



5

Session Presenters




Jill Nelson




Terrah Stroda, CNM



6



7



8

Community Support for Positive Clinical Outcomes



9

Maternal Health in the Sunflower State



10

10

	CDC – National Center for Health Statistics (NCHS)	CDC – Pregnancy Mortality Surveillance System (PMSS)
Data Source	Death certificates	Death certificates linked to fetal death and birth certificates
Time Frame	During pregnancy – 42 days	During pregnancy – 365 days
Source of Classification	ICD-10 codes	Medical epidemiologists (PMSS-MM)
Purpose	Show national trends and provide a basis for international comparison	Analyze clinical factors associated with deaths, publish information that may lead to prevention strategies

Maternal Mortality Review Committees

Death certificates linked to fetal death and birth certificates, medical records, social service records, autopsy, informant interviews...

During pregnancy – 365 days

Multidisciplinary committees

Understand medical and non-medical contributors to deaths, prioritize interventions that effectively reduce maternal deaths



Source: St. Pierre A; Zaharatos J; Goodman D; Callaghan WM. Jan 2018. Challenges and opportunities in identifying, reviewing, and preventing maternal deaths. Obstetrics and Gynecology. 131; 138-142.

Pregnancy Associated Death

A pregnancy-associated death refers to the death of a woman while pregnant or anytime within one year of pregnancy regardless of cause.¹

- Pregnancy-related death.** The death of a woman during pregnancy or within one year of the end of pregnancy from a pregnancy complication, a chain of events initiated by pregnancy, or the aggravation of an unrelated condition by the physiologic effects of pregnancy.
- Pregnancy-associated, but not-related death.** The death of a woman during pregnancy or within one year of the end of pregnancy from a cause that is not related to pregnancy.
- Pregnancy-associated but unable to determine pregnancy relatedness.** The death of a woman while pregnant or within one year of pregnancy, due to a cause that could not be determined to be pregnancy-related or not pregnancy-related.



Pregnancy-Associated Deaths 2016-2022 (Total=153)

Preliminary Data – Subject to Change


- Total deaths occurred in Kansas: 195
- Pregnancy-associated deaths determined by KMMRC: **153**



Source: KMMRC Determinations, Kansas, 2016-2022 (Preliminary Data, Subject To Change)

13

Pregnancy-Associated Deaths 2016-2022 (Total=153)




More than half (51.6%) of all pregnancy-associated deaths occurred after 42 days postpartum.



Source: KMMRC Determinations, Kansas, 2016-2022 (Preliminary Data, Subject To Change)

14

Leading Causes of Pregnancy-Associated Deaths 2016-2022 (Total=153)



Source: KMMRC Determinations, Kansas, 2016-2022 (Preliminary Data, Subject To Change)

15

Pregnancy-Associated Deaths 2016-2022 (Total=153)

- **Nearly half (69 deaths, 45.1%) were related to medical causes of death, such as:**
 - Cardiovascular conditions including hypertensive disorders of pregnancy
 - Infection
 - Malignancies
 - Embolism
 - Hemorrhage
- **Nearly one-third (47 deaths, 30.7%) were caused by:**
 - Mental health conditions, including those contributing to suicide
 - Homicide
 - Unintentional poisoning/overdose
- **The remainder (37 deaths, 24.2%) were caused by:**
 - Motor vehicle crash
 - Fire or burn accidents
 - Unknown




Source: KMMRC Determinations, Kansas, 2016-2022 (Preliminary Data, Subject To Change)

16

Pregnancy-Related Deaths 2016-2022 (Total=48)

The leading causes of death were (in order):



Note: Mental health conditions, including those contributing to suicide.




Source: KMMRC Determinations, Kansas, 2016-2022 (Preliminary Data, Subject To Change)

17

Severe Maternal Morbidity 2018-2022 (Total=1,067)

Per 10,000 delivery hospitalizations, respectively, the top five most common indicators of SMM were:



Source: Kansas Department of Health and Environment, Kansas Hospital Discharge Data, Kansas, 2018-2022, (Preliminary Data, Subject To Change).



18

Definition

Preeclampsia is a serious disorder that can affect all the organs in the body. It usually develops after 20 weeks of pregnancy, often in the third trimester. When it develops before 34 weeks of pregnancy, it is called early-onset preeclampsia. It can also develop in the weeks after childbirth.

Source: Preeclampsia and High Blood Pressure During Pregnancy. The American College of Obstetricians and Gynecologists. [acog.org/womens-health/faqs/preeclampsia-and-high-blood-pressure-during-pregnancy](https://www.acog.org/womens-health/faqs/preeclampsia-and-high-blood-pressure-during-pregnancy)



2022 Natality Report

Table 22. Number of Births Where Reported Medical Risk Factors by Population Group, Kansas, 2022*

Medical Risk Factors [†]	Population Group														n.s. [‡]	Total
	White NH		Black NH		American Indian Alaska Native NH		Asian-PI NH		Multi Race-Other NH		Hispanic-Any Race					
	N	%	N	%	N	%	N	%	N	%	N	%	N	%		
Pre-pregnancy Diabetes	217	0.9	31	1.4	2	1.2	15	1.3	14	1.5	99	1.6	1	1.0		
Gestational Diabetes	1,945	8.3	173	7.9	16	9.7	195	17.3	74	7.8	608	9.7	6	6.3		
Pre-pregnancy Hypertension	636	2.7	113	5.2	6	3.6	23	2.0	26	2.7	107	1.7	3	3.1		
Pre-eclampsia	2,467	10.5	204	9.3	20	12.1	83	7.4	80	8.4	462	7.3	3	3.1		
Eclampsia	84	0.4	8	0.4	0	0.0	1	0.1	3	0.3	19	0.3	0	0.0		
Previous Pre-term Birth	656	2.8	124	5.7	6	3.6	26	2.3	26	2.7	203	3.2	1	1.0		
Previous Poor Pregnancy Outcome	776	3.3	146	6.6	12	7.3	56	5.0	23	2.4	303	4.8	1	1.0		
Vaginal Bleeding	216	0.9	28	1.3	0	0.0	9	0.8	10	1.1	63	1.0	0	0.0		
Previous C-Section	3,536	15.0	456	20.8	29	17.6	168	14.9	131	13.8	941	14.9	20	20.8		
Infertility Treatment	618	2.6	13	0.6	2	1.2	47	4.2	11	1.2	45	0.7	3	3.1		
Infections Contracted or Treated During Pregnancy [‡]	874	3.7	178	8.1	13	7.9	40	3.6	76	8.0	285	4.5	4	4.2		
Smoking During Pregnancy	1,442	6.1	166	7.6	23	13.9	10	0.9	89	9.4	143	2.3	0	0.0		
Alcohol Use During Pregnancy	39	0.2	6	0.3	0	0.0	0	0.0	2	0.2	9	0.1	0	0.0		
Total of Medical Risk Factors [§]	13,506	n/a [¶]	1,644	n/a [¶]	129	n/a [¶]	673	n/a [¶]	565	n/a [¶]	3,287	n/a [¶]	42	n/a [¶]		
Total Births	23,569		2,191		165		1,124		949		6,295		96			


*Residence data
†More than one medical risk factor may have been reported for a birth. Therefore, actual number of births may be lower than totals.
‡n.s. = not stated
§Infections include: Gonorrhea, Syphilis, Herpes Simplex Virus, Chlamydia, HIV, Hepatitis B & Hepatitis C
¶ n/a: Not Applicable
*The data provided only includes births with reported medical risk factors, each risk factor is counted individually. The total of birth with risk factor does not equal the total of births.



Source: Kansas Department of Health and Environment, Natality Report by Racial and Ethnic Population Groups, Kansas, 2022
Available at: kdhe.ks.gov/DocumentCenter/View/40442/

Preeclampsia prevalence **increased significantly** from 4.8 to 6.9 per 100 delivery hospitalizations (2016-2023).

Kansas Prevalence of Preeclampsia among Delivery Hospitalization by Year, 2016-2023



Year	Preeclampsia*	Delivery Hospitalizations	Prevalence (%)
2016	1679	34952	4.8
2017	1766	33499	5.3
2018	1793	31739	5.6
2019	1941	32453	6.0
2020	1857	31406	5.9
2021	2079	31434	6.6
2022	2116	30849	6.9
2023	2145	30878	6.9


*ICD-10-CM diagnosis codes for preeclampsia (O15)

* Indicates that the Annual Percent Change (APC) is significantly different from zero at the alpha = 0.05 level.
Final Selected Model: 0 Joinspoints.

Source: Kansas Department of Health and Environment, Kansas Hospital Discharge Data, Kansas, 2016-2023

The prevalence is highest at the **youngest** (12-19 years, 8.5%) and **oldest** (45-55 years, 11.6%) age groups

Kansas prevalence of Preeclampsia among Delivery Hospitalization by Maternal Age Group (Years) 2019-2023 (five years combined)




Source: Kansas Department of Health and Environment, Kansas Hospital Discharge Data, Kansas, 2019-2023

Non-Hispanic **Native Hawaiian or Other Pacific Islander** and Non-Hispanic **Black or African American** mothers face the highest prevalence.

Kansas Prevalence of Preeclampsia among Delivery Hospitalization by **Race and Ethnicity** 2019-2023 (five years combined)

Patients with Hispanic ethnicity are classified as Hispanic and all non-Hispanic patients are classified according to their reported race.



Source: Kansas Department of Health and Environment, Kansas Hospital Discharge Data, Kansas, 2019-2023

2023 Annual Summary of Vital Statistics

Live Births: 34,041

Stillbirths: 186

Total Births: 34,227

Preterm Birth (<37 wks): 10.5%




Source: Kansas Department of Health and Environment, Kansas Annual Summary of Vital Statistics, 2023. Available at kdhe.ks.gov/DocumentCenter/View/43918/

What do we need to do?!

An *intentional* Kansas intervention to address severe HTN in PG and the postpartum period by enrolling in the national Alliance for Innovation on Maternal Health (AIM) Safety Bundle.

KANSAS: Severe Hypertension in Pregnancy

Began in Jan 2025 as a statewide initiative to address this and other adverse maternal outcomes.



Blue ❤️ Non-Birthing Facilities

AdventHealth Ottawa, Franklin Co
Ellsworth County Medical Center, Ellsworth Co
FW Huston Medical Center, Jefferson Co
Hamilton County Hospital, Hamilton Co
Lincoln County Hospital, Lincoln Co
Logan County Health Services, Logan Co
Mercy Hospital, Inc., McPherson Co
Minneola Healthcare, Clark Co
Norton County Hospital, Norton Co
Phillips County Health Systems, Phillips Co
Stafford County Hospital, Stafford Co




27



KPQC
Kansas Professional Quality Collaborative



What's Next?
Addressing maternal hypertension is a crucial part of improving health outcomes for both mother and infants in Kansas. Through collaboration, education, and evidence-based strategies, KDHE and KPQC are working to create safer pregnancies and healthier futures for families in our state.



- **Elevated Care Needed**
- **Inpatient Transfer**
- Transfer protocol
- Transfer with the team




 To learn more, visit kansaspgc.org

Funding
This initiative is supported by the Kansas Department of Health and Environment with funding through the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number #A3049988 and title *Alliance for Innovation on Maternal Health State Capacity Program*.




28

Timeline




29




Severe Hypertension in Pregnancy


Model for Kansas



30



31




32

Initiative	Q1 2025	Q2 2025	Q3 2025	Q4 2025	2026
Launch Bundle (Readiness)	Launch Bundle Enrollment Data Collection Survey (Redcap)				
Identify (Recognition)		Staff: Education (POST BIRTH/Birth Equity; ACOG algorithms) Patient: Education Community Organizations: Education *Data collection to continue			
Recognize and Respond			Staff: Finalize ACOG Protocols Follow up appointments Transfer Policies		
			Staff: Simulations (Inpatient ,EMS, Emergency Departments) *Data collection to continue		
*Reporting: Ongoing Data Collection			Patient: Follow up/Follow through Comprehensive Care Model; **Patient: Pumping Protocol		
**Neonatal Initiative			Community Outreach: KDHE/Local health departments Connect with facilities with Support Implementation of PP Visits; Home Visits/CHW/Doula/Navigation assigned		EMS Education; Pt Debriefs and Team Birth; Trauma informed Care; Family Planning *Data collection to continue

33

Identify

Normal vs Abnormal Blood Pressure in female patients, including Pregnant and Postpartum (One year!)



34

Accurate Diagnosis

- Chronic Hypertension
- Chronic Hypertension with Superimposed Preeclampsia
- Gestational Hypertension
- Preeclampsia
 - With Severe Features
- Eclampsia



35

Definitions ACOG:

Types of Hypertension		ACOG
Chronic Hypertension	<ul style="list-style-type: none">SBP ≥ 140 or DBP ≥ 90Pre-pregnancy or <20 weeks	
Gestational Hypertension	<ul style="list-style-type: none">SBP ≥ 140 or DBP ≥ 90 on at least two occasions at least 4 hrs apart after 20 weeks gestation in women with previously normal BPAbsence of proteinuria or systemic signs/symptoms	
Preeclampsia – Eclampsia	<ul style="list-style-type: none">SBP ≥ 140 or DBP ≥ 90Proteinuria with or without signs/symptomsPresentation of signs/symptoms/lab abnormalities but no proteinuria <p><i>*Proteinuria not required for diagnosis eclampsia seizure in setting of preeclampsia</i></p>	
Chronic Hypertension with Superimposed Preeclampsia	<ul style="list-style-type: none">Preeclampsia in a woman with a history of hypertension before pregnancy or before 20 weeks of gestation	
Preeclampsia with severe features	<ul style="list-style-type: none">SBP ≥ 160 or DBP ≥ 110 (can be confirmed within a short interval to facilitate timely antihypertensive therapy)Thrombocytopenia (platelet count less than 100,000/microliter)Impaired liver function that is not accounted for by alternative diagnoses and as indicated by abnormally elevated blood concentrations of liver enzymes (to more than twice the upper limit normal concentrations), or by severe persistent right upper quadrant or epigastric pain unresponsive to medications.Renal insufficiency (serum creatinine concentration more than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease)Pulmonary edemaNew-onset headache unresponsive to medication and not accounted for by alternative diagnosesVisual disturbances <p><small>(ACOG Practice Bulletin #202, Gestational Hypertension and Preeclampsia, & ACOG Practice Bulletin #203, Chronic Hypertension in Pregnancy)</small></p>	



36

Taking a Blood Pressure

Correct Position!


- Sitting or Semi Fowlers
- Feet flat, not dangling
- If BP ≥ 160 systolic **and/or** ≥ 110 diastolic, take steps to initiate treatment for severe hypertension—notifying provider, procuring medication



DO NOT REPOSITION PATIENT (yet)

- **Retake BP after 15 minutes.** If BP remains severe, obtain order for medication.
- Administer medication as ordered


Treat ASAP—at least within 1 hour of 1st severe reading

Correct Cuff Size!





37



38

Recognize

Recognize the Problem and think “ALGORITHM”!



39

Avoiding Mistakes

Racism is a risk factor, NOT race

Do not assume:

Race, Obesity, SES status, Diet, Mental health, Pain, or Anxiety is the cause

CMQCC Preeclampsia Early Recognition Tool (PERT)

Everyone knows: POSTBIRTH!

NEURO symptoms= Immediate triage to facility or RESPONSE to change of status



40



Statewide SHTN Initiative work

Prevention works!
and
Prevention starts in the preconception and antepartum settings!



41

Everyone Needs Aspirin....?


Table S1: Cross-sectional survey of recommendations on the use of aspirin in pregnancy for the prevention of pre-eclampsia

Guideline (year)	Aspirin dose	Treatment duration	Recommendations for pregnant women with NSAID hypersensitivity
World Health Organization (2021)	75 mg daily	Start before 20 weeks' gestation	Not addressed
Australian Pregnancy Care Guidelines (2024; pending NHMRC approval)	150 mg daily	Start before 16 weeks' gestation	Contraindicated in patients with hypersensitivity to aspirin
National Institute for Health and Care Excellence, United Kingdom (2023)	75–150 mg daily	Start from 12 weeks' gestation and continue till delivery	Not addressed
Society of Obstetric Medicine of Australia and New Zealand (2023)	150 mg daily	Start before 16 weeks' gestation and stop between 34 weeks to delivery	Not addressed
European Society of Hypertension (2023)	100–150 mg daily	Start before 16 weeks' gestation and continue till 35 weeks	Not addressed
Society of Obstetricians and Gynecologists of Canada (2022)	81–162 mg daily	Start before 16 weeks' gestation and continue till 36 weeks	Not addressed
Sri Lanka College of Obstetricians and Gynaecologists (2022)	75–100 mg daily	Start from the early second trimester and continue till delivery	Not addressed
South African Society of Obstetricians and Gynaecologists (2022)	150 mg daily	Start from 12 weeks' gestation and continue till 36 weeks	Not addressed
American College of Obstetrics and Gynecology/Society for Maternal-Fetal Medicine (2021)	81 mg daily	Start between 12–28 weeks' gestation (optimally before 16 weeks) and continue till delivery	Contraindicated in patients with aspirin allergy, e.g., urticaria or hypersensitivity to NSAIDs (ACOG Committee Opinion No. 743)
US Preventive Services Task Force (2023)	81 mg daily	Start from 12 weeks' gestation	Not addressed



42

Timeline



43

Respond

Treatment= Algorithms, Algorithms and MORE Algorithms!



44

Recognition to Treatment

Appendix B: Suspected Preeclampsia Algorithm

EXAMPLE

EMERGENCY DEPARTMENT

Postpartum Preeclampsia Checklist

In Patient < 6 Weeks Postpartum with:

- BP ≥ 160/110 or
- BP ≥ 140/90 with unrelenting headache, visual disturbances, epigastric pain

Call for Assistance

- Designate:
 - Team leader
 - Checklist reader/recorder
 - Primary RN
- Ensure side rails up
- Call obstetric consult. Document call
- Place IV, Draw preeclampsia labs
 - CBC
 - Chemistry Panel
 - PTT
 - Uric Acid
 - Hepatic Function
 - Fibrinogen
 - Type and Screen
- Ensure medications appropriate given patient history
- Administer seizure prophylaxis
- Administer antihypertensive therapy
 - Contact MIM or Critical Care for refractory blood pressure
- Consider indwelling urinary catheter
 - Maintain strict I&O – patient at risk for pulmonary edema
- Brain imaging if unrelenting headache or neurological symptoms

Magnesium Sulfate

Contraindications: Myasthenia gravis, avoid with pulmonary edema, use caution with renal failure

IV access:

- Lead 4-6 grams 50% magnesium sulfate in 100 mL solution over 20 min
- Label magnesium sulfate. Connect to labeled infusion pump
- Magnesium sulfate maintenance >2 grams/hour

No IV access:

- 10 grams of 50% solution IM (5 g in each buttock)

Antihypertensive Medications

For SBP ≥ 160 or DBP ≥ 110 (See SAM algorithms for complete management when necessary to move to another agent after 2 doses.)

- Labetalol** (initial dose: 20mg). Avoid parenteral labetalol with active asthma, heart disease, or congestive heart failure; use with caution with history of asthma
- Hydralazine** (5-10 mg IV over 2 min). May increase risk of maternal hypotension
- Oral Nifedipine** (30 mg capsules). Capsules should be administered orally, not punctured or otherwise administered sublingually

Anticonvulsant Medications

For recurrent seizures or when magnesium sulfate contraindicated

- Lorazepam (Ativan):** 2-4 mg IV x 1, may repeat once after 10-15 min
- Diazepam (Valium):** 5-10 mg IV q 5-10 min to maximum dose 30 mg

Safe Motherhood Initiative

Revised January 2019

45

EXAMPLE

Hypertensive Emergency Checklist

HYPERTENSIVE EMERGENCY:

- Two severe BP values (systolic/diastolic) taken 15-60 minutes apart. Values do not need to be consecutive.
- May treat within 15 minutes if clinically indicated

Call for Assistance

- Designate:
 - Team leader
 - Checklist reader/recorder
 - Primary RN
- Ensure side rails up
- Ensure medications appropriate given patient history
- Administer seizure prophylaxis (magnesium sulfate first line agent, unless contraindicated)
- Antihypertensive therapy within 1 hour for persistent severe range BP
- Place IV, Draw preeclampsia labs
- Antenatal corticosteroids (if <34 weeks of gestation)
- Re-address VTE prophylaxis requirement
- Place indwelling urinary catheter
- Brain imaging if unrelenting headache or neurological symptoms
- Debrief patient, family, and obstetric team

***Active asthma* is defined as:**

- ① symptoms at least once a week, or
- ② use of an inhaler, corticosteroids for asthma during the pregnancy, or
- ③ any history of intubation or hospitalization for asthma.

Magnesium Sulfate

Contraindications: Myasthenia gravis, avoid with pulmonary edema, use caution with renal failure

IV access:

- Lead 4-6 grams 50% magnesium sulfate in 100 mL solution over 20 min
- Label magnesium sulfate. Connect to labeled infusion pump
- Magnesium sulfate maintenance >2 grams/hour

No IV access:

- 10 grams of 50% solution IM (5 g in each buttock)

Antihypertensive Medications

For SBP ≥ 160 or DBP ≥ 110 (See SAM algorithms for complete management when necessary to move to another agent after 2 doses.)

- Labetalol** (initial dose: 20mg). Avoid parenteral labetalol with active asthma, heart disease, or congestive heart failure; use with caution with history of asthma
- Hydralazine** (5-10 mg IV over 2 min). May increase risk of maternal hypotension
- Oral Nifedipine** (30 mg capsules). Capsules should be administered orally, not punctured or otherwise administered sublingually

***Maximum cumulative IV-administered doses should not exceed 220 mg labetalol or 25 mg hydralazine in 24 hours**

Anticonvulsant Medications

For recurrent seizures or when magnesium sulfate contraindicated

- Lorazepam (Ativan):** 2-4 mg IV x 1, may repeat once after 10-15 min
- Diazepam (Valium):** 5-10 mg IV q 5-10 min to maximum dose 30 mg

Safe Motherhood Initiative

Revised January 2019

46

EXAMPLE

- ☐ Neuromuscular block and intubate
- ☐ Obtain radiographic imaging
- ☐ ICU admission
- ☐ Consider anticonvulsant medication

Revised January 2010



EMERGENCY DEPARTMENT

Postpartum Preeclampsia Checklist

For recurrent seizures or when magnesium sulfate contraindicated

- ☐ **Lorazepam (Ativan):** 2-4 mg IV x 1, may repeat once after 30-35 min
- ☐ **Diazepam (Valium):** 5-50 mg IV q 5-10 min

Safe Motherhood Initiative



Revised January 2019




YOU are vital to this work!

"Eyes on" at home, clinic, community



49

Prenatal Visits VS Postpartum Visits
@Postpartum.PUSH



ONE VISIT!
At 6 weeks



50

Postpartum Surveillance

Necessary to prevent additional morbidity as preeclampsia/eclampsia can develop postpartum

INPATIENT



- Measure BP every 4 hours after delivery until stable
- Do not use NSAIDs for women with elevated BP
- Do not discharge patient until BP is well controlled for at least 24 hours



OUTPATIENT

- For pts with preeclampsia, visiting nurse evaluation recommended:
 - ✓ Within 3-5 days
 - ✓ Again in 7-10 days after delivery (earlier if persistent symptoms)

ANTIHYPERTENSIVE THERAPY

- Recommended for persistent postpartum HTN: SBP ≥ 150 or DBP ≥ 100 on at least two occasions at least 4 hours apart
- Persistent SBP ≥ 160 or DBP ≥ 110 should be treated within 1 hour





Post-Discharge Evaluation

ELEVATED BP AT HOME, OFFICE, TRIAGE

Postpartum triggers:

- SBP ≥ 160 or DBP ≥ 110 or
- SBP ≥ 140 -159 or DBP ≥ 90 -109 with unremitting headaches, visual disturbances, or epigastric/RUQ pain



- Emergency Department treatment (OB /MICU consult as needed)
- AntiHTN therapy suggested if persistent SBP ≥ 150 or DBP ≥ 100 on at least two occasions at least 4 hours apart
- Persistent SBP ≥ 160 or DBP ≥ 110 should be treated within 1 hour



Good response to antiHTN treatment and asymptomatic

Admit for further observation and management (L&D, ICU, unit with telemetry)

Signs and symptoms of eclampsia, abnormal neurological evaluation, congestive heart failure, renal failure, coagulopathy, poor response to antihypertensive treatment

Recommend emergency consultation for further evaluation (MFM, internal medicine, OB anesthesiology, critical care)





53







Innovative ideas!

ER/OB/EMS Collaborations



And CONTINUE FTI work! (Remember this...?)



Contact Information

Jill Nelson
Maternal & Perinatal Initiatives Consultant/
KMMRC & KPQC Coordinator
jillelizabeth.nelson@ks.gov

Terrah Stroda, CNM
Maternal QI Coordinator
KS Perinatal Quality Collaborative(KPQC)
tstroda@gmail.com



57

Questions?



58

Upcoming Education and Important Dates

- 5/28 KHC Office Hours - KHDE Maternal Health Programs
- 6/25 KHC Office Hours
- 7/15 KHC CAP Lunch and Learn - RHC Billing Basics
- 7/1-7/2 CMS Quality Conference
- 9/4-9/5 KHA Convention and Trade Show
- 10/23 Kansas Health Impact Conference - Topeka



Connect with us
on:



[KHCqi](#)



[@KHCqi](#)



[Kansas Healthcare Collaborative](#)

→ Find contact info
and more at:
www.KHOnline.org/staff



Malea Hartvickson
Executive Director



Mandy Johnson
Senior Director,
Programs



Treva Borchert
Director of Operations



Eric Cook-Wiens
Data & Measurement
Director



Liz Warman
Quality Improvement
Advisor



Jill Daughhelee
Director of Education
and Communications



Azucena Gonzalez
Health Care Quality
Data Analyst



Jenni Peters
Quality Improvement
Advisor



Patty Thomsen
Quality Improvement
Advisor



Rebecca Wagner
Grants Coordinator



61